Fundraising Fox
Ed Mathers
InvestorPartner at New Enterprise Associates (NEA)
Maryland
Writes $2M – $50M checks · typically $25M
Find your path to Ed Mathers
Sign up to see every warm intro you have to Ed Mathers
- Paths you didn't know you had: your email and LinkedIn already hold routes to Ed Mathers. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Ed Mathers is a Partner on NEA's healthcare team, where he has worked since 2008, focusing on biotechnology and specialty pharmaceuticals investments. Before NEA, he was EVP of Corporate Development and Venture at MedImmune, contributing to its 2007 sale to AstraZeneca, and previously held roles at Inhale Therapeutic Systems and Glaxo Wellcome (now GSK). His investment interests include gene therapy, nonviral gene therapy, RNA editing, and immunology and inflammation.
Contact· self-published, not guessed
Invests in
Biotech
Beyond investing
- Education
- Studied at North Carolina State University (B.S., Chemistry)
From published sources — common ground for a warm intro.
Deals · 6
Curzion Pharmaceuticals IncBoard seat
via New Enterprise Associates (NEA) · filed Jul 2019 · $3.5M raise
Mirum PharmaceuticalsBoard seat
via New Enterprise Associates (NEA) · filed Nov 2018 · $120.1M raise
Senti BiosciencesBoard seat
via New Enterprise Associates (NEA) · filed Feb 2018 · $53.4M raise
AkouosBoard seat
via New Enterprise Associates (NEA) · filed Nov 2017 · $7.6M raise
SynlogicBoard seat
via New Enterprise Associates (NEA) · filed Feb 2016 · $40.6M raise
Envisia TherapeuticsBoard seat
via New Enterprise Associates (NEA) · filed Oct 2015 · $5.1M raise
Attribution from SEC filings, press coverage, and firm rosters.
Other disclosed investments
Board seats
Affinia TherapeuticsAmplyx PharmaceuticalsInozyme PharmaMBX BiosciencesObsEva SAReneo PharmaceuticalsRhythm PharmaceuticalsTrevi Therapeutics
Investor
Affinia TherapeuticsAmplyx PharmaceuticalsBrenig Therapeutics, Inc.Cardurion PharmaceuticalsCode BiotherapeuticsCurzion PharmaceuticalsIntarcia TherapeuticsInversagoLiquidia TechnologiesLumena PharmaceuticalsLumos PharmaMBX BiosciencesMirna TherapeuticsMotus TherapeuticsObsEvaOrbis MedicinesRa PharmaceuticalsReneo PharmaceuticalsRhythm PharmaceuticalsSatori PharmaceuticalsSentryShape TherapeuticsSorriso PharmaceuticalsSplice BioTrevi TherapeuticsZiarco
Sources: curated public sources · SEC Form D filings.
Colleagues at New Enterprise Associates (NEA)
Network10
Investors connected to Ed in public investor directories — a warm-intro map.
Frequently asked questions
- Who is Ed Mathers?
- Ed Mathers is a Partner on NEA's healthcare team, where he has worked since 2008, focusing on biotechnology and specialty pharmaceuticals investments. Before NEA, he was EVP of Corporate Development and Venture at MedImmune, contributing to its 2007 sale to AstraZeneca, and previously held roles at Inhale Therapeutic Systems and Glaxo Wellcome (now GSK). His investment interests include gene therapy, nonviral gene therapy, RNA editing, and immunology and inflammation.
- Where does Ed Mathers work?
- Ed Mathers is Partner at New Enterprise Associates (NEA).
- What does Ed Mathers invest in?
- Ed Mathers invests in Biotech.
- What check size does Ed Mathers write?
- Ed Mathers typically writes checks of $2M – $50M.
- What boards does Ed Mathers sit on?
- Ed Mathers holds tracked board seats at Affinia Therapeutics, Akouos, Akouos, Amplyx Pharmaceuticals, Curzion Pharmaceuticals Inc, Envisia Therapeutics, Inozyme Pharma, MBX Biosciences, Mirum Pharmaceuticals, Mirum Pharmaceuticals.
- What companies has Ed Mathers invested in?
- Investments tracked here include Affinia Therapeutics, Akouos, Amplyx Pharmaceuticals, Brenig Therapeutics, Inc., Cardurion Pharmaceuticals, Code Biotherapeutics, Curzion Pharmaceuticals, Intarcia Therapeutics, Inversago, Liquidia Technologies, Lumena Pharmaceuticals, Lumos Pharma, and 18 more.
About this profile. Compiled from public sources — New Enterprise Associates (NEA)'s own website, regulatory filings and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights